Navigation Links
Slowing evolution to stop drug resistance
Date:11/16/2009

Infectious organisms that become resistant to antibiotics are a serious threat to human society. They are also a natural part of evolution. In a new project, researchers at the University of Gothenburg are attempting to find substances that can slow the pace of evolution, in order to ensure that the drugs of today remain effective into the future.

The resistance of infectious organisms to antibiotics is particularly serious in drugs against fungi. Fungal cells are similar to human cells, which means that it is difficult to develop effective drugs that can destroy them without also damaging human cells, i.e. without causing side effects. We must therefore safeguard the effectiveness of the few antifungal drugs that are available today. Resistance to these would leave many diseases without effective treatment.

A natural phenomenon

However, drug resistance is a natural part of evolution. Evolution creates random variations in the characteristics of organisms, which results in some of them developing greater tolerance to drugs to which they are exposed. This leads eventually to completely resistant fungal strains, and the drug will become totally ineffective. The quicker these random variations appear, the greater the risk of resistance developing. One way of combating drug resistance is to slow down the pace of evolution.

Slowing down evolution

Researcher Jonas Warringer at the Department of Cell and Molecular Biology is using advanced genetic experiments to try to find such "evolution-slowing" substances. In the first instance, this involves identifying the cell components that regulate the speed of evolution. Jonas Warringer and his colleagues are using ordinary brewer's yeast as a model for their studies. A yeast has 6 000 genes, and destroying single genes in otherwise identical organisms enables Jonas Warringer and his colleagues to use the method of exclusion.

Looking for gold dust

"We stimulate the evolution of the yeast cell and observe it in real time. As our yeasts develop resistance to a particular drug, we measure how the survivability of the different strains changes during the process. Evolution progresses more slowly in some strains when a specific component is destroyed. These strains are like gold dust to us, because they tell us that these particular components are critical to the speed of evolution," says Jonas Warringer.

"This is how we eventually found the genes that regulate evolution. If, in the next phase, we can find a substance that can attack one of these components, we will be able to delay the development of drug resistance and ensure that today's drugs remain effective into the future."

The research project is funded by the Magnus Bergwall Foundation and other benefactors. Jonas Warringer hopes that evolution-slowing drugs will become available within the next 10-15 years.


'/>"/>

Contact: Jonas Warringer
jonas.warringer@cmb.gu.se
46-031-786-3961
University of Gothenburg
Source:Eurekalert  

Related biology news :

1. Landscape-scale treatment promising for slowing beetle spread
2. Researchers combat slowing yields with targeted fertilizer applications
3. Biologists, educators recognize excellence in evolution education
4. Study sheds light on evolution of human complexity
5. Evolution of hyperactivity is focus of free public lecture at UC Riverside
6. K-State receives more than $780,000 to fund graduate students studying ecology, evolution, genomics
7. Time in a bottle: Scientists watch evolution unfold
8. Science wins fight over evolution in schools, says Case Western Reserve University author
9. The amazing maze of maize evolution
10. Genetic conflict in fish led to evolution of new sex chromosomes
11. Frozen assets: NIAID researchers turn to unique resource for clues to norovirus evolution
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Slowing evolution to stop drug resistance
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: